Syndax Pharmaceuticals, Inc. (SNDX)
PHARMACEUTICAL PREPARATIONS
Syndax Pharmaceuticals, Inc. (SNDX) is listed on Nasdaq, where it has traded since March 3, 2016.
- Listed On
- Nasdaq
- Listed Since
- March 3, 2016
- Employees
- 298
- Market Cap
- $1.3B
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 232 institutions reported holding SNDX, with 107.6 million shares worth $2.4 billion in aggregate. The largest reported holder was BlackRock, with 9.0 million shares worth $197.2 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 9,020,006 | $197M | Added 9.27% |
| Kynam Capital Management | 8,050,959 | $176M | Unchanged |
| Vanguard | 6,595,559 | $144M | Added 5.2% |
| Goldman Sachs | 5,861,265 | $128M | Added 17.3% |
| State Street | 5,658,424 | $124M | Added 27.73% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is SNDX?
Syndax Pharmaceuticals, Inc. (SNDX) is listed on Nasdaq, where it has traded since March 3, 2016.
Who are the largest institutional holders of SNDX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of SNDX were BlackRock, Kynam Capital Management and Vanguard.
How many institutions own SNDX?
232 institutions reported a position in SNDX for the quarter ended June 30, 2026, worth $2.4 billion in total.
Did institutions buy or sell SNDX last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for SNDX.
Every reported institutional holder, plus insider and congressional trades in SNDX, on SentiSense.